 REDWOOD CITY, Calif., March 31, 2022 GLOBE NEWSWIRE -- Jasper Therapeutics, Inc. NASDAQ: JSPR, a biotechnology company focused on hematopoietic cell transplant therapies, today announced that updated data from the Companys ongoing study of JSP191 as single agent conditioning prior to allogeneic hematopoietic stem cell HSC re-transplant in patients with severe combined immunodeficiency SCID has been accepted for presentation as a late-breaking poster at the 2022 Clinical Immunology Society CIS Annual Meeting, to be held in Charlotte, North Carolina from March 31 to April 3, 2022. 